Cambridge Antibody Technology

Cambridge Antibody Technology, commonly known as CAT, was a British biotechnology company headquartered in Cambridge, England. Founded in 1989 by David Chiswell and Greg Winter, the company was established around advances developed in the laboratories of the UK Medical Research Council. Its central scientific contribution was the use of phage display and, later, ribosome display to discover and optimize human and humanized antibody therapeutics. CAT helped establish antibody engineering as a commercially important biotechnology platform. Its phage-display libraries enabled researchers to select antibodies against particular biological targets without relying exclusively on traditional animal immunization. The company’s work produced or contributed to several clinically important antibody programs. The best-known was adalimumab, initially identified at CAT as D2E7 and later marketed by Abbott Laboratories and AbbVie as Humira. Adalimumab became a major anti-TNF treatment for inflammatory diseases and is widely regarded as the first fully human antibody to become a blockbuster medicine. CAT’s collaborations also contributed to belimumab, an anti-BLyS antibody later marketed as Benlysta for systemic lupus erythematosus, as well as programs involving oncology, infectious disease, fibrosis, and inflammatory targets. The company developed from a research-centered enterprise into a publicly traded biotechnology group. It moved from MRC facilities to the Babraham Institute and subsequently expanded across the Melbourn Science Park before relocating its principal operations to Granta Park. CAT listed on the London Stock Exchange in 1997 and later on Nasdaq. During the biotechnology market expansion around 2000, its share price and corporate profile rose sharply, and the company became a frequent subject of takeover speculation. CAT pursued licensing agreements, research collaborations, technology acquisitions, and therapeutic-product deals. These included the acquisition of Aptein, which strengthened its position in ribosome or polysome display technology, and agreements with companies including Human Genome Sciences, Genzyme, Immunex, Searle, and Genencor. Not every program reached approval or commercial success, but the company’s platform and partnerships transferred its research into products developed and marketed by larger pharmaceutical organizations. AstraZeneca acquired CAT in 2006 for £702 million. AstraZeneca subsequently combined CAT with MedImmune, which it had acquired separately, to create a biologics research and development organization. CAT therefore ceased to operate as an independent listed company, while its scientific technologies, personnel, intellectual property, and drug-development legacy continued within AstraZeneca’s biologics activities. Founding scientist Greg Winter later received one quarter of the 2018 Nobel Prize in Chemistry for the phage display of peptides and antibodies, recognition that further highlighted CAT’s place in the history of therapeutic antibody engineering.

Cambridge Antibody Technology was founded in 1989 by David Chiswell and Greg Winter, drawing on antibody-engineering research associated with the Medical Research Council in Cambridge. John McCafferty was among the scientists whose work contributed to the company’s technology base. CAT initially operated from MRC laboratories, moved to the Daly Research Laboratories at the Babraham Institute in 1990, and then expanded at the Melbourn Science Park. Its laboratory and office footprint grew through the 1990s as the company developed its antibody libraries and commercial relationships. The company’s defining platform was phage display. In this approach, antibody fragments are displayed on bacteriophages while the corresponding genetic material remains available for identification and engineering. Researchers can expose large libraries to a target, recover binding molecules, and iteratively improve affinity and other properties. CAT also pursued ribosome or polysome display, a cell-free method intended to support larger libraries and automated selection. Its acquisition of Aptein in 1998 strengthened the intellectual-property position around this area. CAT commercialized its technology primarily through partnerships and development agreements. Its work on D2E7 produced adalimumab, later branded Humira, an anti-TNF antibody developed and marketed by Abbott Laboratories and subsequently AbbVie. The company also worked with Human Genome Sciences on antibody programs including belimumab, later Benlysta, and raxibacumab, as well as oncology antibodies such as mapatumumab and lexatumumab. A strategic alliance with Genzyme covered antibodies against transforming growth factor beta and produced programs including fresolimumab. Agreements with Immunex and later Amgen licensed CAT’s human-antibody discovery capabilities for therapeutic research. CAT became a public company in 1997 through a London Stock Exchange listing that raised approximately £43 million. It raised more than £90 million in a further financing in 2000 and also listed on Nasdaq. Around the peak of the biotechnology market in 2000, CAT’s share price exceeded £50, reflecting investor interest in antibody platforms and genome-related biotechnology. The company moved from Melbourn to Granta Park, where the Franklin Building opened in 2001 and the Milstein Building became its corporate headquarters in the following period. CAT also attempted corporate expansion. In 2002 it sought to acquire Drug Royalty Corporation to eliminate a royalty obligation, but shareholders accepted a competing offer from Inwest. In 2003 CAT proposed a share-based acquisition of Oxford Glycosciences. Celltech responded with a hostile cash bid, creating a prominent British biotechnology takeover contest; CAT did not improve its terms, and Celltech ultimately acquired OGS. In 2005 CAT acquired two anti-CD22 immunotoxin programs from Genencor, GCR-3888 and GCR-8015, with development links to the US National Cancer Institute. The latter program later became known as moxetumomab. These transactions reflected CAT’s effort to broaden from a discovery-platform company into a developer of proprietary therapeutic candidates. AstraZeneca acquired CAT in June 2006 for £702 million. AstraZeneca later combined CAT with MedImmune, creating a global biologics research and development division. A new Granta Park facility, later named the Aaron Klug Building, was opened in 2008. Although CAT no longer existed as an independent company, its antibody-display methods, intellectual property, collaborations, and clinical programs remained influential. Greg Winter’s share of the 2018 Nobel Prize in Chemistry for phage display provided major external recognition of the scientific principles on which CAT had been built.

• 2018

  Nobel recognition for phage display

  [1]Cambridge Antibody Technologyen.wikipedia.org

  Greg Winter received one quarter of the Nobel Prize in Chemistry for phage display of peptides and antibodies.

• 2008

  Aaron Klug Building opened

  [1]Cambridge Antibody Technologyen.wikipedia.org

  AstraZeneca opened CAT’s expanded Granta Park facility after refurbishment.

• 2006

  Acquired by AstraZeneca

  [1]Cambridge Antibody Technologyen.wikipedia.org

  AstraZeneca acquired CAT for £702 million.

• 2001

  Franklin Building opened

  [1]Cambridge Antibody Technologyen.wikipedia.org

  CAT’s first Granta Park building was formally opened.

• 2000

  Nasdaq listing and Granta Park relocation

  [1]Cambridge Antibody Technologyen.wikipedia.org

  CAT listed on Nasdaq and began moving its operations from Melbourn to Granta Park.

• 1998

  Aptein acquired

  [1]Cambridge Antibody Technologyen.wikipedia.org

  The acquisition strengthened CAT’s patent position in polysome-display technology.

• 1997

  London Stock Exchange listing

  [1]Cambridge Antibody Technologyen.wikipedia.org

  CAT listed in London and raised approximately £43 million.

• 1990

  Operations move to Babraham

  [1]Cambridge Antibody Technologyen.wikipedia.org

  CAT moved its operations to the Daly Research Laboratories at the Babraham Institute near Cambridge.

• 1989

  Company founded

  [1]Cambridge Antibody Technologyen.wikipedia.org

  David Chiswell and Greg Winter founded Cambridge Antibody Technology around antibody-engineering research developed with the UK Medical Research Council.

Platform-oriented biotechnology company focused on discovering and advancing antibody therapeutics for pharmaceutical partners.

• Discovery platform

  Phage-display antibody libraries

  CAT’s core technology displayed antibody fragments on bacteriophages, allowing researchers to select binders from very large libraries and then identify, mutate, and optimize the corresponding antibody sequences. The platform supported the discovery of human and humanized therapeutic antibodies and was commonly licensed or deployed through collaborations with pharmaceutical companies.

• Anti-TNF antibody

  Adalimumab (D2E7; Humira)

  CAT discovered the antibody originally designated D2E7 using phage display. The program was developed clinically and commercialized by Abbott Laboratories, later AbbVie, as Humira. It became a major anti-TNF medicine for inflammatory diseases and is recognized as the first fully human antibody blockbuster drug.

• Anti-BLyS antibody

  Belimumab (LymphoStat-B; Benlysta)

  Developed through CAT’s collaboration with Human Genome Sciences, belimumab targets B-lymphocyte stimulator, also called BLyS. Human Genome Sciences and GlaxoSmithKline advanced and marketed it as Benlysta for systemic lupus erythematosus.

• Anti-CD22 immunotoxin · 2005

  Moxetumomab (CAT-8015)

  CAT acquired the GCR-8015 anti-CD22 program from Genencor in 2005. The candidate was subsequently known as moxetumomab and was developed for CD22-positive hematological malignancies, with links to National Cancer Institute research and clinical development under AstraZeneca.

• Discovery and optimization platform · 1998

  Ribosome and polysome display

  CAT developed cell-free display approaches in which antibody molecules remain associated with their encoding nucleic acids through ribosomal complexes. These methods were intended to permit larger libraries, automated selection, and optimization of affinity, stability, pharmacology, and developability.

• 2006

  Accept AstraZeneca acquisitionM&A

  Background

  CAT was a strategically valuable antibody-discovery company but faced the capital and development demands associated with advancing biologics programs independently.

  Action taken

  AstraZeneca acquired CAT and took it into its biologics research organization.

  Aftermath

  CAT ceased to operate as an independent listed company and was later combined with MedImmune within AstraZeneca.

  Acquisition consideration. £702 million (2006)

  Source

• 2003

  Withdraw from Oxford Glycosciences bidM&A

  Background

  CAT proposed a share-based combination with Oxford Glycosciences, but Celltech launched a competing cash offer and accumulated a substantial stake.

  Action taken

  CAT did not improve its offer, allowing the agreement to lapse; Oxford Glycosciences subsequently recommended Celltech’s offer.

  Aftermath

  Celltech completed its acquisition of Oxford Glycosciences in April 2003.

  • Celltech — Celltech pursued a hostile cash offer and increased its ownership stake until Oxford Glycosciences recommended its proposal.

  Source

• 1998

  Acquire Aptein to strengthen display technologyM&A

  Background

  CAT sought to expand its intellectual-property position beyond phage display and obtain technology related to cell-free polysome display.

  Action taken

  CAT completed the acquisition of Aptein and obtained its issued shares, options, warrants, and associated patent estate.

  Aftermath

  The transaction supported CAT’s subsequent work on ribosome-display optimization and antibody-library development.

  Maximum consideration. Up to US$11 million, satisfied through CAT shares (1998)

  Source

• 2018

  Greg Winter receives part of the Nobel Prize in Chemistry[1]Cambridge Antibody Technologyen.wikipedia.org

  Other

  The Nobel Prize organisation recognized Greg Winter for the phage display of peptides and antibodies, a technology central to CAT’s scientific heritage.

• 2006

  AstraZeneca acquires Cambridge Antibody Technology[1]Cambridge Antibody Technologyen.wikipedia.org

  M&A

  AstraZeneca completed the acquisition of CAT for £702 million, ending CAT’s independent corporate existence.

• 2003

  CAT and Oxford Glycosciences merger proposal collapses[1]Cambridge Antibody Technologyen.wikipedia.org

  M&A

  CAT’s proposed share-based combination with Oxford Glycosciences failed after Celltech made a competing cash offer and ultimately acquired OGS.

• 1998

  CAT expands its antibody-display technology through Aptein acquisition[1]Cambridge Antibody Technologyen.wikipedia.org

  M&A

  The company acquired Aptein, obtaining intellectual property associated with polysome or ribosome display and expanding its molecular-display platform.

• 1997

  Cambridge Antibody Technology lists on the London Stock Exchange[1]Cambridge Antibody Technologyen.wikipedia.org

  Other

  CAT became a publicly traded biotechnology company and raised approximately £43 million in its initial London listing.

1. 1Cambridge Antibody Technologyen.wikipedia.org